Amidst Legal Battle, BMS' CAR-T Therapy Scores Second FDA Approval

Bristol Myers Squibb’s CAR-T therapy Breyanzi (lisocabtagene maraleucel, liso-cel) picked up a second approval from the U.S. Food and Drug Administration. On Friday, the cancer drug was approved for the treatment of adult patients with large B-cell lymphoma (LBCL).